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The International Association for the Study of Pain (IASP)
defines trigeminal neuralgia as a sudden, unilateral, severe,
brief, stabbing, recurrent episode of pain in the distribu-
tion of one or more branches of the trigeminal nerve.
Trigeminal neuralgia (TN) can be distinguished in classical
TN and symptomatic TN [1]. Classical TN is due to a vas-
cular compression of the trigeminal root by tortuous or
aberrant vessels. Symptomatic TN can be related to cere-
bello-pontine angle tumours which compress the trigem-
inal nerve root. Multiple sclerosis (MS) is typically
associated with TN (2-4% of patients with TN) [2].
Whether produced by multiple sclerosis or chronic com-
pression exerted by a blood vessel or a benign tumour,
demyelination increases the susceptibility of the nerve
fibres to ectopic excitation, ephaptic transmission, and
high-frequency discharges. Although the primary cause of
TN must necessarily affect the primary afferents, the
pathophysiological mechanism may or may not seconda-
rily involve the central neurons.
Recent epidemiological studies of general practice
research databases reported a TN incidence ranging from
12.6 to 26.8 per 100.000/year, with the incidence increas-
ing with age (16.3 in the fourth decade, 30.6 in patients
older than 80 years) [3,4].
Pain distribution is unilateral (bilateral TN may some-
times occur in MS). The maxillary division is the most fre-
quently affected, both in classic and symptomatic TN.
Pain, usually referred to as stabbing or electric-shock-like,
is brief and paroxysmal, lasting a few seconds. Paroxysms
may be provoked by stimulating cutaneous or mucous
trigeminal territories (trigger zones), regardless of the dis-
tribution of the perceived pain.
Carbamazepine, still remains the gold standard drug
with the highest success rate. The second drug of choice
recommended by international guidelines is oxcarbaze-
pine. In a comparison between these two drugs, efficacy
was shown to be very similar but tolerability is better with
oxcarbazepine [1].
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